A construction project of Baiyu’s new research and manufacturing base has been launched on 21st of October, 2017. Sun Yi, president of Baiyu Pharmaceutical Co., Ltd. gave a speech on the ground breaking ceremony.
The constructed new base has a land area of 103333 ㎡ and strictly complies with EU/FDA regulations. It is used for the production of freeze-dried, small volume, dripping pills and will be the key provider of Ginkgolide injection once finished in 2019.
As stated in Mr Sun’s speech, it’s a new beginning for Baiyu –because of the higher manufacturing requirements which meet global strictest regulations, our product will benefit more patients not only in China but also over the world.